vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $50.3M, roughly 1.7× READING INTERNATIONAL INC). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -5.1%, a 27.9% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -14.2%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $4.1M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 5.6%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
FDMT vs RDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $50.3M |
| Net Profit | $19.4M | $-2.6M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | -1.9% |
| Net Margin | 22.8% | -5.1% |
| Revenue YoY | 8508900.0% | -14.2% |
| Net Profit YoY | 139.1% | -14.5% |
| EPS (diluted) | $0.43 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $50.3M | ||
| Q3 25 | $90.0K | $52.2M | ||
| Q2 25 | $15.0K | $60.4M | ||
| Q1 25 | $14.0K | $40.2M | ||
| Q4 24 | $1.0K | $58.6M | ||
| Q3 24 | $3.0K | $60.1M | ||
| Q2 24 | $5.0K | $46.8M | ||
| Q1 24 | $28.0K | $45.1M |
| Q4 25 | $19.4M | $-2.6M | ||
| Q3 25 | $-56.9M | $-4.2M | ||
| Q2 25 | $-54.7M | $-2.7M | ||
| Q1 25 | $-48.0M | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-43.8M | $-7.0M | ||
| Q2 24 | $-35.0M | $-12.8M | ||
| Q1 24 | $-32.4M | $-13.2M |
| Q4 25 | 17.3% | -1.9% | ||
| Q3 25 | -67983.3% | -0.6% | ||
| Q2 25 | -396373.3% | 4.8% | ||
| Q1 25 | -383007.1% | -17.2% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -1704400.0% | -0.6% | ||
| Q2 24 | -849120.0% | -16.4% | ||
| Q1 24 | -136200.0% | -16.7% |
| Q4 25 | 22.8% | -5.1% | ||
| Q3 25 | -63195.6% | -8.0% | ||
| Q2 25 | -364386.7% | -4.4% | ||
| Q1 25 | -342657.1% | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | -1461433.3% | -11.7% | ||
| Q2 24 | -699060.0% | -27.4% | ||
| Q1 24 | -115717.9% | -29.4% |
| Q4 25 | $0.43 | $-0.11 | ||
| Q3 25 | $-1.01 | $-0.18 | ||
| Q2 25 | $-0.98 | $-0.12 | ||
| Q1 25 | $-0.86 | $-0.21 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | $-0.79 | $-0.31 | ||
| Q2 24 | $-0.63 | $-0.57 | ||
| Q1 24 | $-0.66 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $10.5M |
| Total DebtLower is stronger | — | $185.1M |
| Stockholders' EquityBook value | $505.7M | $-18.2M |
| Total Assets | $566.7M | $434.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $10.5M | ||
| Q3 25 | $305.1M | $8.1M | ||
| Q2 25 | $293.2M | $9.1M | ||
| Q1 25 | $321.4M | $5.9M | ||
| Q4 24 | $424.9M | $12.4M | ||
| Q3 24 | $501.9M | $10.1M | ||
| Q2 24 | $541.9M | $9.3M | ||
| Q1 24 | $525.9M | $7.5M |
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $505.7M | $-18.2M | ||
| Q3 25 | $369.0M | $-12.1M | ||
| Q2 25 | $420.9M | $-7.7M | ||
| Q1 25 | $469.7M | $-8.1M | ||
| Q4 24 | $510.6M | $-4.4M | ||
| Q3 24 | $552.9M | $1.6M | ||
| Q2 24 | $588.3M | $6.5M | ||
| Q1 24 | $600.6M | $18.0M |
| Q4 25 | $566.7M | $434.9M | ||
| Q3 25 | $424.0M | $435.2M | ||
| Q2 25 | $473.6M | $438.1M | ||
| Q1 25 | $515.7M | $441.0M | ||
| Q4 24 | $560.4M | $471.0M | ||
| Q3 24 | $604.0M | $495.7M | ||
| Q2 24 | $620.1M | $494.9M | ||
| Q1 24 | $629.9M | $494.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $4.3M |
| Free Cash FlowOCF − Capex | $28.5M | $4.1M |
| FCF MarginFCF / Revenue | 33.5% | 8.2% |
| Capex IntensityCapex / Revenue | 0.1% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $-2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $4.3M | ||
| Q3 25 | $-46.5M | $295.0K | ||
| Q2 25 | $-43.4M | $1.6M | ||
| Q1 25 | $-47.8M | $-7.7M | ||
| Q4 24 | $-134.6M | $8.0M | ||
| Q3 24 | $-29.4M | $1.3M | ||
| Q2 24 | $-30.2M | $-10.4M | ||
| Q1 24 | $-29.1M | $-2.8M |
| Q4 25 | $28.5M | $4.1M | ||
| Q3 25 | $-46.6M | $-246.0K | ||
| Q2 25 | $-43.4M | $1.2M | ||
| Q1 25 | $-48.4M | $-8.0M | ||
| Q4 24 | $-138.4M | $7.0M | ||
| Q3 24 | $-31.2M | $-1.1M | ||
| Q2 24 | $-30.6M | $-10.6M | ||
| Q1 24 | $-29.8M | $-4.7M |
| Q4 25 | 33.5% | 8.2% | ||
| Q3 25 | -51765.6% | -0.5% | ||
| Q2 25 | -289620.0% | 1.9% | ||
| Q1 25 | -345635.7% | -19.8% | ||
| Q4 24 | -13837100.0% | 12.0% | ||
| Q3 24 | -1038966.7% | -1.8% | ||
| Q2 24 | -611840.0% | -22.7% | ||
| Q1 24 | -106421.4% | -10.4% |
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 101.1% | 1.0% | ||
| Q2 25 | 440.0% | 0.6% | ||
| Q1 25 | 4507.1% | 0.6% | ||
| Q4 24 | 378600.0% | 1.7% | ||
| Q3 24 | 59266.7% | 4.0% | ||
| Q2 24 | 6980.0% | 0.5% | ||
| Q1 24 | 2535.7% | 4.3% |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
